+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to find out how common cardiac amyloidosis is among older adults aged 80 years and above who have been hospitalized for heart failure and show thickening of the hearts left ventricle. The study is observational and conducted across multiple geriatric and cardiology centers. It focuses on patients who have experienced heart failure with specific heart muscle changes seen on echocardiography. Participants will be recruited over 24 months and followed for 12 months. At the start, researchers will collect medical history, demographic information, clinical data, frailty status, biological and genetic tests, and echocardiogram results. Bone scans using specific tracers will be performed during or after hospital stays to check for heart muscle involvement. Follow-up will include phone calls every three months to track hospitalizations, care facility admissions, and survival. During the study, participants will have regular assessments including frailty scales, cognitive tests, and questionnaires related to neuropathic pain and independence in daily activities. Researchers will evaluate bone scan results to detect amyloidosis and measure other health and functional outcomes. The study aims to provide a clearer picture of cardiac amyloidosis prevalence and patient condition over one year.

Age: 80Years +All Genders
36 locations
E

Actively Recruiting

Researchers are studying the World Health Organizations Integrated Care for Older People ICOPE program to see if it helps prevent age-related decline in older adults. This study compares the comprehensive ICOPE program with usual care from primary doctors. The goal is to determine if regular screening, personalized care plans, and follow-up can better maintain functions like mobility, cognition, and nutrition in people aged 65 and older living at home. The trial randomly assigns participants to either receive the full ICOPE program or usual care. The ICOPE program includes screening every six months using a digital tool, a thorough assessment of six key functions, a personalized intervention plan, and ongoing follow-up, including phone calls and annual visits over 60 months. After an initial 36-month intervention, all participants receive the ICOPE program during a 24-month extension phase. Participants have annual visits at 12, 24, 36, 48, and 60 months, during which a research nurse collects data while unaware of which group they are in. Phone calls occur between visits to support the care plan and gather information about life events. The primary outcome measured is functional decline at 36 months. The study runs until 2031, with continuous monitoring of participants health and program adherence.

Age: 65Years +All GendersPhase Not Applicable
6 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of the RGn600 device in treating patients with mild-to-moderate Alzheimers disease. This device combines PhotoBioModulation, which uses light from red to near-infrared wavelengths, and Static Magnetic Stimulation to potentially reduce inflammation on the brain-gut axis involved in Alzheimers development. The study is a randomized, double-blind, sham-controlled trial conducted at multiple centers in France. Participants will be randomly assigned to use either the active RGn600 device or an inactive sham device. The device is applied non-invasively as a helmet on the head and an abdominal belt, with treatment sessions lasting 20 minutes each. Treatment is scheduled for 5 sessions per week during weeks 1 to 8, 3 sessions per week from weeks 9 to 16, and 2 sessions per week from weeks 17 to 26. After the treatment phase, participants will be followed for up to 52 weeks. Throughout the study, participants will attend four onsite visits to assess cognition, autonomy, quality of life, and safety through neurological tests, questionnaires, clinical exams, and blood samples. Additional biological samples such as fecal and saliva will be collected at one site for further analysis. Researchers will track changes in cognitive scores using the ADAS-cog scale and monitor adverse events and device safety. The study aims to understand the impact of RGn600 treatment over one year.

Age: 55Years - 85YearsAll GendersPhase Not Applicable
7 locations